HYPERION DEFI, INC. (HYPD)
D
Pipeline Grade
Financial Position (from SEC Filings)
$7.4M
Cash & Equivalents
$4.2M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$47M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06471296 | Virus-associated Tumour Microenvironment | OTHER | Recruiting | 254 |
| NCT04886401 | Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC | OTHER | Recruiting | 50 |
| NCT06891443 | Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | PHASE3 | Recruiting | 32 |
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On... | PHASE2 | Recruiting | 128 |
| NCT06858735 | HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Adv... | PHASE2 | Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.